CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life Readmission and Mortality After Hospitalization for Myocardial Infarction and Heart Failure Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction Dilated cardiomyopathy: so many cardiomyopathies! Outcomes and Effect of Treatment According to Etiology in HFrEF An Analysis of PARADIGM-HF Mechanical circulatory support devices in advanced heart failure: 2020 and beyond

Review ArticleVolume 74, Issue 5, August 2019

JOURNAL:J Am Coll Cardiol. Article Link

Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)

FWA Verheugt, JM ten Berg, RF Storey et al.

ABSTRACT

For secondary prevention of coronary artery disease (CAD), oral antiplatelet therapy is essential. In case of coronary intervention, temporary dual antiplatelet therapy is mandatory as well. Recently, low-dose oral anticoagulation has entered the CAD arena. Atrial fibrillation (AF) is often seen in CAD and vice versa. In most patients stroke prevention in AF consists of oral anticoagulation. In many cases of CAD in patients with AF, anticoagulation has to be combined with antiplatelet agents (so called, dual pathway antithrombotic therapy). Excess bleeding in these conditions is a rapidly rising problem. This review addresses the antithrombotic options in CAD alone, in AF alone, and in their combination, when either an invasive or a noninvasive approach has been chosen.